Press Releases
Indiantelevision.com > News Headlines >Delhi HC refuses to hear DK Bose song copyright plea
The one-stop online source for the Indian cable, satellite, terrestrial, DTH television, business. Everything you wanted to now about India TV
Networking-Knowledge - STM
Check out STM's new short&smart videos about Scholarly Scientific Publishing.
NeuroHealing Receives Notice of Allowance from the U.S. Patent and Trademark Office for a New
The patent (US Application 12/310,175) will cover broad methods of using modafinil and modafinil isomers to delay ejaculation in males during sexual activity. The allowed claims include use of the short half-life modafinil d-isomer to provide a short duration of the desired pharmacological activity.
BioMS Medical Receives 38 Additional Patents For
December 6, 2005 - BioMS Medical Corp. today announced that the University of Alberta has received thirty-eight additional patents for the Company's synthetic peptide therapeutic, MBP8298, for the treatment of multiple sclerosis (MS). BioMS Medical, through a subsidiary, licenses these patents on
Solutia's Flexsys Division Announces Positive Rulings on Its PPD Antidegradant Intellectual
ST. LOUIS, April 1 /PRNewswire-FirstCall/ -- Flexsys, a wholly owned subsidiary of Solutia Inc. (NYSE:SOA - News), and a leading producer of specialty chemical products
Companies House - Valetime Group | Valetime Group
Companies House is the registrar of companies incorporated in England & Wales and Scotland. Company registration matters are dealt with in UK law by the
Industry Collaboration Results in Newly Patented Technology that HelpsDrug Companies Comply with...
Industry Collaboration Results in Newly Patented Technology that HelpsDrug Companies Comply with Latest Regulatory 'Quality by Design' Initiatives
BioMS Receives Additional Patent for Multiple Sclerosis Drug MBP8298 in the US
November 2, 2006 - BioMS Medical Corp. today announced that the University of Alberta has received additional patents for the Company's synthetic peptide therapeutic, MBP8298, for the treatment of multiple sclerosis (MS). BioMS Medical licenses these patents on an exclusive worldwide basis from the
BioMS Medical Announces Four New Patents for MBP8298
July 3, 2003 - BioMS Medical Corp. today announced that the University of Alberta has received additional patents in Russia, Belarus, Ukraine and the European Union regarding the Company's synthetic peptide therapeutic, MBP8298, for the treatment of MS. BioMS Medical, through a subsidiary, licenses
BioMS Medical Announces 17 Additional Patents for MS Drug
March 23, 2004 - BioMS Medical Corp. today announced that the University of Alberta has received seventeen additional patents for the Company's synthetic peptide therapeutic, MBP8298, for the treatment of multiple sclerosis (MS). BioMS Medical, through a subsidiary, licenses these patents on an
Refine by Content Type:
Refine by Source:
- www.indiantelevision.com (7)
- www.biomsmedical.com (5)
- www.prleap.com (3)
- finance.yahoo.com (2)
- locitv01.indiantelevision.co.in (1)
- www.aspentech.com (1)
- www.stm-assoc.org (1)
- www.valetimegroup.com (1)
